Ana Kerguelen

Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation

Alberto Álvarez‐Larrán, Arturo Pereira, Paola Guglielmelli et al. · Haematologica · 2016 · 145 citations · Full text

Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

Alberto Álvarez‐Larrán, Ana Kerguelen, Juan Carlos Hernández‐Boluda et al. · British Journal of Haematology · 2015 · 77 citations · Full text

Pharmacotherapy, Logistic Analysis, Myeloid Neoplasia +17

Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

Alberto Álvarez‐Larrán, Manuel Pérez‐Encinas, Francisca Ferrer‐Marín et al. · Haematologica · 2016 · 72 citations · Full text

Thrombopoiesis, Thrombosis, Polycythemia Vera +10

The occurrence of adverse events during the infusion of autologous peripheral blood stem cells is related to the number of granulocytes in the leukapheresis product

Raúl Córdoba, R Arrieta, Ana Kerguelen et al. · Bone Marrow Transplantation · 2007 · 53 citations

Regenerative Medicine, Adverse Events, Bone Marrow Failure +15

<i>JAK2</i>V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events

Alberto Álvarez‐Larrán, Beatríz Bellosillo, Arturo Pereira et al. · American Journal of Hematology · 2014 · 48 citations · Full text

Essential Thrombocythemia, Myelofibrotic Transformation, Immunology +23